The many ways of Wnt in cancer

Current Opinion in Genetics and Development

Volumn 17, Issue 1, 2007, Pages 45-51

  Polakis, Paul ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXIN; BETA CATENIN; FRIZZLED PROTEIN; GLYCOGEN SYNTHASE KINASE 3; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; PHOSPHOPROTEIN PHOSPHATASE 2A; T CELL FACTOR 4; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG; WNT1 PROTEIN;

CANCER; COLON POLYPOSIS GENE; GENE; GENE CLUSTER; GENE MUTATION; GENE SEQUENCE; GENETIC DISORDER; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

BETA CATENIN; GENES, APC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; PROTEINS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; WNT PROTEINS;

MUS;

EID: 33846193290     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2006.12.007     Document Type: Review

References (65)

1. Groden J., Thliveris A., Samowitz W., Carlson M., Gelbert L., Albertsen H., Joslyn G., Stevens J., Spirio L., Robertson M., et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66 (1991) 589-600
2. Kinzler K.W., Nilbert M.C., Su L.K., Vogelstein B., Bryan T.M., Levy D.B., Smith K.J., Preisinger A.C., Hedge P., McKechnie D., et al. Identification of FAP locus genes from chromosome 5q21. Science 253 (1991) 661-665
3. Hinck L., Nelson W.J., and Papkoff J. Wnt-1 modulates cell-cell adhesion in mammalian cells by stabilizing β-catenin binding to the cell adhesion protein cadherin. J Cell Biol 124 (1994) 729-741
4. Munemitsu S., Albert I., Souza B., Rubinfeld B., and Polakis P. Regulation of intracellular β-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA 92 (1995) 3046-3050
5. -/- colon carcinoma. Science 275 (1997) 1784-1787
6. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., and Kinzler K.W. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275 (1997) 1787-1790
7. Rubinfeld B., Robbins P., El-Gamil M., Albert I., Porfiri E., and Polakis P. Stabilization of β-catenin by genetic defects in melanoma cell lines. Science 275 (1997) 1790-1792
8. Zeng L., Fagotto F., Zhang T., Hsu W., Vasicek T.J., Perry III W.L., Lee J.J., Tilghman S.M., Gumbiner B.M., and Costantini F. The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. Cell 90 (1997) 181-192
9. Satoh S., Daigo Y., Furukawa Y., Kato T., Miwa N., Nishiwaki T., Kawasoe T., Ishiguro H., Fujita M., Tokino T., et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 24 (2000) 245-250
10. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. Biochim Biophys Acta 1332 (1997) F127-F147
11. Lamlum H., Ilyas M., Rowan A., Clark S., Johnson V., Bell J., Frayling I., Efstathiou J., Pack K., Payne S., et al. The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis. Nat Med 5 (1999) 1071-1075
12. Smits R., Hofland N., Edelmann W., Geugien M., Jagmohan-Changur S., Albuquerque C., Breukel C., Kucherlapati R., Kielman M.F., and Fodde R. Somatic Apc mutations are selected upon their capacity to inactivate the β-catenin downregulating activity. Genes Chromosomes Cancer 29 (2000) 229-239
13. McCartney B.M., Price M.H., Webb R.L., Hayden M.A., Holot L.M., Zhou M., Bejsovec A., and Peifer M. Testing hypotheses for the functions of APC family proteins using null and truncation alleles in Drosophila. Development 133 (2006) 2407-2418. Embryonic and ovarian fly cells completely lacking both APC1 and APC2 were generated, and various fragments of APC were introduced therein to study their activity in an otherwise null background. The results redress previous proposals on APC function and partial and dominant negative activities of APC mutants.
14. Kawasaki Y., Sato R., and Akiyama T. Mutated APC and Asef are involved in the migration of colorectal tumour cells. Nat Cell Biol 5 (2003) 211-215
15. Albuquerque C., Breukel C., van der Luijt R., Fidalgo P., Lage P., Slors F.J., Leitao C.N., Fodde R., and Smits R. The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the β-catenin signaling cascade. Hum Mol Genet 11 (2002) 1549-1560
16. Furuuchi K., Tada M., Yamada H., Kataoka A., Furuuchi N., Hamada J., Takahashi M., Todo S., and Moriuchi T. Somatic mutations of the APC gene in primary breast cancers. Am J Pathol 156 (2000) 1997-2005
17. Ohgaki H., Kros J.M., Okamoto Y., Gaspert A., Huang H., and Kurrer M.O. APC mutations are infrequent but present in human lung cancer. Cancer Lett 207 (2004) 197-203
18. Wallis Y.L., Morton D.G., McKeown C.M., and Macdonald F. Molecular analysis of the APC gene in 205 families: extended genotype-phenotype correlations in FAP and evidence for the role of APC amino acid changes in colorectal cancer predisposition. J Med Genet 36 (1999) 14-20
19. Wu R., Zhai Y., Fearon E.R., and Cho K.R. Diverse mechanisms of β-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 61 (2001) 8247-8255
20. Demunter A., Libbrecht L., Degreef H., De Wolf-Peeters C., and van den Oord J.J. Loss of membranous expression of β-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations. Mod Pathol 15 (2002) 454-461
21. Johnson V., Volikos E., Halford S.E., Eftekhar Sadat E.T., Popat S., Talbot I., Truninger K., Martin J., Jass J., Houlston R., et al. Exon 3 β-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome. Gut 54 (2005) 264-267. Rigorously challenges the notion that β-catenin mutations are associated with MSI+ colorectal cancers. Although a significant bias is found for MSI+ cancers of familial origin, the association did not apply to sporadic MSI+ cancers.
22. Luchtenborg M., Weijenberg M.P., Wark P.A., Saritas A.M., Roemen G.M., van Muijen G.N., de Bruine A.P., van den Brandt P.A., and de Goeij A.F. Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort Study. BMC Cancer 5 (2005) 160. A tour de force analysis of more than 600 colorectal cancers in which the relationship among APC, Ras and β-catenin mutations are explored.
23. Thorstensen L., Lind G.E., Lovig T., Diep C.B., Meling G.I., Rognum T.O., and Lothe R.A. Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability. Neoplasia 7 (2005) 99-108
24. Rowley P.T. Inherited susceptibility to colorectal cancer. Annu Rev Med 56 (2005) 539-554
25. Bell D.A. Origins and molecular pathology of ovarian cancer. Mod Pathol 18 Suppl 2 (2005) S19-S32
26. Oliva E., Sarrio D., Brachtel E.F., Sanchez-Estevez C., Soslow R.A., Moreno-Bueno G., and Palacios J. High frequency of β-catenin mutations in borderline endometrioid tumours of the ovary. J Pathol 208 (2006) 708-713
27. Irving J.A., Catasus L., Gallardo A., Bussaglia E., Romero M., Matias-Guiu X., and Prat J. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the β-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. Hum Pathol 36 (2005) 605-619. Mutational status of β-catenin was examined as a genetic means to determine the origin of multiple simultaneously occurring endometrial cancers. The results nicely address the question of whether these cancers arise independently or represent metastases from a common primary tumor.
28. Jho E.H., Zhang T., Domon C., Joo C.K., Freund J.N., and Costantini F. Wnt/β-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 22 (2002) 1172-1183
29. Leung J.Y., Kolligs F.T., Wu R., Zhai Y., Kuick R., Hanash S., Cho K.R., and Fearon E.R. Activation of AXIN2 expression by β-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. J Biol Chem 277 (2002) 21657-21665
30. Koch A., Weber N., Waha A., Hartmann W., Denkhaus D., Behrens J., Birchmeier W., von Schweinitz D., and Pietsch T. Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas. J Pathol 204 (2004) 546-554
31. Li C.M., Kim C.E., Margolin A.A., Guo M., Zhu J., Mason J.M., Hensle T.W., Murty V.V., Grundy P.E., Fearon E.R., et al. CTNNB1 mutations and overexpression of Wnt/β-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol 165 (2004) 1943-1953
32. Salahshor S., and Woodgett J.R. The links between axin and carcinogenesis. J Clin Pathol 58 (2005) 225-236
33. Kishida M., Koyama S., Kishida S., Matsubara K., Nakashima S., Higano K., Takada R., Takada S., and Kikuchi A. Axin prevents Wnt-3a-induced accumulation of β-catenin. Oncogene 18 (1999) 979-985
34. Webster M.T., Rozycka M., Sara E., Davis E., Smalley M., Young N., Dale T.C., and Wooster R. Sequence variants of the axin gene in breast, colon, and other cancers: an analysis of mutations that interfere with GSK3 binding. Genes Chromosomes Cancer 28 (2000) 443-453
35. Fearnhead N.S., Wilding J.L., Winney B., Tonks S., Bartlett S., Bicknell D.C., Tomlinson I.P., Mortensen N.J., and Bodmer W.F. Multiple rare variants in different genes account for multifactorial inherited susceptibility to colorectal adenomas. Proc Natl Acad Sci USA 101 (2004) 15992-15997
36. Rubinfeld B., Albert I., Porfiri E., Munemitsu S., and Polakis P. Loss of β-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene. Cancer Res 57 (1997) 4624-4630
37. Lammi L., Arte S., Somer M., Jarvinen H., Lahermo P., Thesleff I., Pirinen S., and Nieminen P. Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet 74 (2004) 1043-1050
38. Duval A., Gayet J., Zhou X.P., Iacopetta B., Thomas G., and Hamelin R. Frequent frameshift mutations of the TCF-4 gene in colorectal cancers with microsatellite instability. Cancer Res 59 (1999) 4213-4215
39. Fukushima H., Yamamoto H., Itoh F., Horiuchi S., Min Y., Iku S., and Imai K. Frequent alterations of the β-catenin and TCF-4 genes, but not of the APC gene, in colon cancers with high-frequency microsatellite instability. J Exp Clin Cancer Res 20 (2001) 553-559
40. Shimizu Y., Ikeda S., Fujimori M., Kodama S., Nakahara M., Okajima M., and Asahara T. Frequent alterations in the Wnt signaling pathway in colorectal cancer with microsatellite instability. Genes Chromosomes Cancer 33 (2002) 73-81
41. Cuilliere-Dartigues P., El-Bchiri J., Krimi A., Buhard O., Fontanges P., Flejou J.F., Hamelin R., and Duval A. TCF-4 isoforms absent in TCF-4 mutated MSI-H colorectal cancer cells colocalize with nuclear CtBP and repress TCF-4-mediated transcription. Oncogene 25 (2006) 4441-4448. The occurrence of TCF4 mutations in MSI+ colorectal cancers is very common but their relevance to function has been lacking. Here, a proposal relating to the consequence of these mutations is advanced.
42. Caldwell G.M., Jones C., Gensberg K., Jan S., Hardy R.G., Byrd P., Chughtai S., Wallis Y., Matthews G.M., and Morton D.G. The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res 64 (2004) 883-888
43. Patel S., Doble B., and Woodgett J.R. Glycogen synthase kinase-3 in insulin and Wnt signalling: a double-edged sword?. Biochem Soc Trans 32 (2004) 803-808
44. Zeng X., Tamai K., Doble B., Li S., Huang H., Habas R., Okamura H., Woodgett J., and He X. A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 438 (2005) 873-877. This study closely examined the early signaling events engaged by Wnt ligands and report on the kinases that phosphorylate the co-receptor LRP6.
45. Reifenberger J., Knobbe C.B., Wolter M., Blaschke B., Schulte K.W., Pietsch T., Ruzicka T., and Reifenberger G. Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int J Cancer 100 (2002) 549-556
46. Imai M., Nakamura T., Akiyama T., and Horii A. Infrequent somatic mutations of the ICAT gene in various human cancers with frequent 1p-LOH and/or abnormal nuclear accumulation of β-catenin. Oncol Rep 12 (2004) 1099-1103
47. Hsu W., Zeng L., and Costantini F. Identification of a domain of Axin that binds to the serine/threonine protein phosphatase 2A and a self-binding domain. J Biol Chem 274 (1999) 3439-3445
48. Seeling J.M., Miller J.R., Gil R., Moon R.T., White R., and Virshup D.M. Regulation of β-catenin signaling by the B56 subunit of protein phosphatase 2A. Science 283 (1999) 2089-2091
49. Li X., Yost H.J., Virshup D.M., and Seeling J.M. Protein phosphatase 2A and its B56 regulatory subunit inhibit Wnt signaling in Xenopus. EMBO J 20 (2001) 4122-4131
50. Ratcliffe M.J., Itoh K., and Sokol S.Y. A positive role for the PP2A catalytic subunit in Wnt signal transduction. J Biol Chem 275 (2000) 35680-35683
51. Willert K., Shibamoto S., and Nusse R. Wnt-induced dephosphorylation of axin releases β-catenin from the axin complex. Genes Dev 13 (1999) 1768-1773
52. Bajpai R., Makhijani K., Rao P.R., and Shashidhara L.S. Drosophila Twins regulates Armadillo levels in response to Wg/Wnt signal. Development 131 (2004) 1007-1016
53. Arroyo J.D., and Hahn W.C. Involvement of PP2A in viral and cellular transformation. Oncogene 24 (2005) 7746-7755
54. Chen W., Possemato R., Campbell K.T., Plattner C.A., Pallas D.C., and Hahn W.C. Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell 5 (2004) 127-136
55. Boyden L.M., Mao J., Belsky J., Mitzner L., Farhi A., Mitnick M.A., Wu D., Insogna K., and Lifton R.P. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346 (2002) 1513-1521
56. Little R.D., Carulli J.P., Del Mastro R.G., Dupuis J., Osborne M., Folz C., Manning S.P., Swain P.M., Zhao S.C., Eustace B., et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70 (2002) 11-19
57. Van Wesenbeeck L., Cleiren E., Gram J., Beals R.K., Benichou O., Scopelliti D., Key L., Renton T., Bartels C., Gong Y., et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 72 (2003) 763-771
58. Ai M., Holmen S.L., Van Hul W., Williams B.O., and Warman M.L. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol 25 (2005) 4946-4955
59. Veltman I.M., Vreede L.A., Cheng J., Looijenga L.H., Janssen B., Schoenmakers E.F., Yeh E.T., and van Kessel A.G. Fusion of the SUMO/Sentrin-specific protease 1 gene SENP1 and the embryonic polarity-related mesoderm development gene MESDC2 in a patient with an infantile teratoma and a constitutional t(12;15)(q13;q25). Hum Mol Genet 14 (2005) 1955-1963
60. Carter M., Chen X., Slowinska B., Minnerath S., Glickstein S., Shi L., Campagne F., Weinstein H., and Ross M.E. Crooked tail (Cd) model of human folate-responsive neural tube defects is mutated in Wnt coreceptor lipoprotein receptor-related protein 6. Proc Natl Acad Sci USA 102 (2005) 12843-12848
61. Zhang Y., Wang Y., Li X., Zhang J., Mao J., Li Z., Zheng J., Li L., Harris S., and Wu D. The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd. Mol Cell Biol 24 (2004) 4677-4684
62. Robitaille J., MacDonald M.L., Kaykas A., Sheldahl L.C., Zeisler J., Dube M.P., Zhang L.H., Singaraja R.R., Guernsey D.L., Zheng B., et al. Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy. Nat Genet 32 (2002) 326-330
63. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274. A sobering look at the genetic complexity and the myriad possibilities available to cancers in selecting for mutations along the disease progression path.
64. Suzuki H., Watkins D.N., Jair K.W., Schuebel K.E., Markowitz S.D., Chen W.D., Pretlow T.P., Yang B., Akiyama Y., Van Engeland M., et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 36 (2004) 417-422
65. Saburi S., and McNeill H. Organising cells into tissues: new roles for cell adhesion molecules in planar cell polarity. Curr Opin Cell Biol 17 (2005) 482-484